ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0668

Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study

Jiwon Hwang1, Yeonghee Eun2, Kyungdo Han3 and Joong Kyong Ahn2, 1Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, 2Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea

Meeting: ACR Convergence 2023

Keywords: Administrative Data, Epidemiology, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies have shown an association between systemic sclerosis and cancer. However, because the disease is rare, large-scale studies are lacking, especially in Asians. We aimed to compare the incidence of cancer in patients with SSc and age- and sex-matched controls in a nationwide population-based cohort in Korea.

Methods: We included patients with SSc defined by the ICD-10 code (M34) and rare and intractable disease code (V138) and 1:5 age- and sex-matched controls using the Korean National Health Insurance Database. The outcomes of the study were incidence of cancer. Cox proportional hazard analysis and Kaplan-Meier curve were used to compare the incidence of cancer between patients with SSc and controls.

Results: A total of 5,145 patients with systemic sclerosis and 25,725 controls were included in the study. During the study period, the overall cancer incidence rate was 11.07 per 1,000 person-years in patients with systemic sclerosis and 7.59 per 1,000 person-years in controls. Overall cancer risk was 1.5 times higher in patients with systemic sclerosis (adjusted hazard ratio 1.46, 95% confidence interval 1.28–1.67). Lung cancer and lymphoma had a high risk in both male and female patients with systemic sclerosis, and colorectal cancer had a high risk only in male patients with systemic sclerosis. The risk of biliary cancer, skin cancer, and cervical cancer was high in female systemic sclerosis patients.

Conclusion: This nationwide cohort study showed that patients with systemic sclerosis were associated with increased cancer risk. Clinicians should be aware of cancers that may increase the risk in patients with systemic sclerosis and apply appropriate screening measures.


Disclosures: J. Hwang: None; Y. Eun: None; K. Han: None; J. Ahn: None.

To cite this abstract in AMA style:

Hwang J, Eun Y, Han K, Ahn J. Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/increased-risk-of-cancer-in-patients-with-systemic-sclerosis-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-cancer-in-patients-with-systemic-sclerosis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology